QUIDE Drug Patent Profile

Which patents cover Quide, and when can generic versions of Quide launch?

Quide is a drug marketed by Dow Pharm and is included in one NDA.

The generic ingredient in QUIDE is piperacetazine. There is one drug master file entry for this compound. Additional details are available on the piperacetazine profile page.

Summary for QUIDE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for QUIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dow Pharm	QUIDE	piperacetazine	TABLET;ORAL	013615-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Dow Pharm	QUIDE	piperacetazine	TABLET;ORAL	013615-002	Approved Prior to Jan 1, 1982		DISCN	No	No

QUIDE (Aducanumab) Investment Analysis

Last updated: February 18, 2026

This report analyzes the investment fundamentals of QUIDE (aducanumab), a monoclonal antibody developed by Biogen for Alzheimer's disease. The analysis focuses on patent landscape, regulatory status, clinical trial data, market potential, and competitive environment to assess its investment viability.

What is QUIDE and its Therapeutic Target?

QUIDEX is an investigational monoclonal antibody designed to target aggregated forms of amyloid-beta protein, a key pathological hallmark of Alzheimer's disease (AD) [1]. Aducanumab, the active pharmaceutical ingredient in QUIDEX, selectively binds to aggregated forms of beta-amyloid, including diffuse and fibrillar deposits, and facilitates their clearance from the brain. The rationale for targeting amyloid-beta is based on the amyloid cascade hypothesis, which posits that the accumulation of amyloid-beta plaques initiates a cascade of neurodegenerative events leading to cognitive decline [2].

What is the Current Regulatory Status of QUIDEX?

The regulatory path for QUIDEX has been complex and characterized by significant debate. In June 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to aducanumab, marketed as Aduhelm, for the treatment of Alzheimer's disease [3]. The accelerated approval pathway was based on QUIDEX's ability to reduce amyloid-beta plaques in the brain, as evidenced by positron emission tomography (PET) imaging. This surrogate endpoint is reasonably likely to predict clinical benefit [4].

However, the FDA's decision was met with significant controversy from the agency's own advisory committee, which voted overwhelmingly against recommending approval. Concerns were raised about the clinical meaningfulness of the observed reduction in amyloid plaques and the lack of clear evidence of cognitive benefit in the pivotal trials [5].

In April 2022, the FDA revised the labeling for Aduhelm, restricting its use to patients with mild cognitive impairment or mild dementia due to Alzheimer's disease, who have confirmed presence of amyloid pathology [6]. This revision followed a review of additional data and reinforced the need for confirmatory clinical trials to verify clinical benefit.

The European Medicines Agency (EMA) recommended against granting a marketing authorization for aducanumab in December 2021, citing insufficient evidence of efficacy [7].

What is the Clinical Trial Evidence Supporting QUIDEX?

The efficacy of QUIDEX was primarily evaluated in two large, Phase 3, randomized, double-blind, placebo-controlled trials: ENGAGE and EMERGE [1, 8]. These trials enrolled approximately 3,500 patients with early Alzheimer's disease (mild cognitive impairment or mild dementia). Both trials were terminated early in March 2019 due to futility analyses, which indicated that neither study was likely to meet its primary endpoint of significant difference in cognitive decline.

However, a subsequent ad-hoc analysis of a larger dataset, including patients who received higher doses of aducanumab for a longer duration, suggested a potential dose- and time-dependent reduction in clinical decline, as measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score. This post-hoc analysis, combined with the confirmed reduction in amyloid plaques, formed the basis for the FDA's accelerated approval [3, 4].

Key findings from these trials include:

• Amyloid Plaque Reduction: Aducanumab demonstrated a dose-dependent reduction in amyloid-beta plaques in the brain across both trials [3]. This effect was observed consistently in treated patients compared to placebo.
• Clinical Decline (ENGAGE): The EMERGE trial showed a statistically significant slowing of cognitive and functional decline in the high-dose aducanumab arm compared to placebo, as measured by the CDR-SB score [3, 8]. The mean difference was 0.39 points on the CDR-SB scale over 18 months, representing a 22% reduction in the rate of decline [3].
• Clinical Decline (EMERGE): The ENGAGE trial did not show a statistically significant difference in the primary endpoint between the aducanumab and placebo groups [3, 8].

The discrepant results between ENGAGE and EMERGE remain a point of contention, contributing to the controversy surrounding the drug's approval.

What is the Market Potential for QUIDEX?

The market potential for QUIDEX is significant, given the unmet medical need in Alzheimer's disease. Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide, with a rapidly aging global population. The current treatment landscape for AD is limited, with existing therapies primarily addressing symptoms rather than the underlying pathology.

The addressable market for QUIDEX is primarily patients diagnosed with early-stage Alzheimer's disease who meet specific diagnostic criteria, including the confirmed presence of amyloid pathology. This represents a substantial patient population.

Estimates for the Alzheimer's disease drug market vary, but the potential for disease-modifying therapies could reach tens of billions of dollars annually. Factors influencing market penetration and revenue include:

• Prescriber Adoption: Clinician confidence in the drug's efficacy and safety profile is critical.
• Payer Reimbursement: The extent to which Medicare and private insurers cover the drug will significantly impact patient access and sales. The Centers for Medicare & Medicaid Services (CMS) issued a national coverage determination (NCD) in April 2022, limiting Medicare coverage of amyloid-beta targeting therapies for AD to patients enrolled in clinical trials [9]. This decision substantially curtails the immediate market for QUIDEX.
• Patient Access: Factors such as co-pays, insurance hurdles, and the need for specialized diagnostic procedures (e.g., PET scans or cerebrospinal fluid analysis) can affect patient access.
• Competitive Landscape: The introduction of other disease-modifying therapies for AD will impact QUIDEX's market share.

What is the Competitive Landscape for QUIDEX?

The Alzheimer's disease therapeutic landscape is evolving rapidly with several disease-modifying therapies in development and on the market. QUIDEX faces competition from:

• Other Amyloid-Targeting Monoclonal Antibodies:
  • Lecanemab (Leqembi), Eisai/Biogen: Received traditional FDA approval in July 2023 for early Alzheimer's disease. Lecanemab has demonstrated statistically significant slowing of cognitive and functional decline in Phase 3 trials [10].
  • Donanemab, Eli Lilly: Submitted for FDA approval, having also shown a slowing of cognitive decline in Phase 3 trials in patients with early symptomatic AD [11].
• Other Therapeutic Modalities: Research is ongoing into therapies targeting tau pathology, neuroinflammation, and synaptic dysfunction.
• Symptomatic Treatments: Existing drugs that manage AD symptoms, such as cholinesterase inhibitors and memantine, will continue to be used.

The competitive advantage for QUIDEX will depend on its demonstrated clinical benefit compared to placebo, its safety profile, ease of administration, and the ability to secure broad reimbursement. The success of other amyloid-targeting antibodies, particularly lecanemab, which has secured traditional approval and broader coverage, presents a significant challenge for QUIDEX's market positioning.

What are the Key Risks and Challenges for QUIDEX?

Investing in QUIDEX involves substantial risks and challenges:

• Clinical Efficacy Uncertainty: The primary concern remains the clinical meaningfulness of QUIDEX's efficacy. The FDA's accelerated approval was based on a surrogate endpoint, and confirmatory trials are required to verify clinical benefit. If these trials fail to demonstrate a clear clinical advantage, regulatory action or market withdrawal could occur.
• Safety Concerns: QUIDEX is associated with amyloid-related imaging abnormalities (ARIA), including edema (ARIA-E) and microhemorrhages (ARIA-H). While generally manageable, these adverse events require careful monitoring through MRI scans, adding complexity and cost to treatment [3]. The incidence and severity of ARIA can influence prescriber and patient acceptance.
• Regulatory Scrutiny: The FDA's initial approval process was highly contentious. Future regulatory decisions, including potential requests for additional data or restrictions, are possible. The EMA's rejection highlights global regulatory divergence.
• Reimbursement Challenges: The CMS National Coverage Determination limiting Medicare coverage to clinical trial participants has severely restricted QUIDEX's market access in the United States, its primary market [9]. Reversal or modification of this NCD is uncertain and may require substantial evidence of clinical utility.
• Competitive Pressures: The rapid development of competing disease-modifying therapies, such as lecanemab and potentially donanemab, with more robust clinical data and clearer regulatory pathways, intensifies competition and may erode QUIDEX's market share.
• Diagnostic Requirements: Confirming amyloid pathology, a prerequisite for QUIDEX use, requires specialized diagnostic tools (PET scans or CSF analysis). The availability, cost, and widespread adoption of these diagnostics can be a barrier to treatment.
• Physician and Patient Acceptance: The complex regulatory history, efficacy debate, and safety concerns may lead to cautious adoption by physicians and uncertainty among patients.

What is the Financial Performance and Outlook?

Biogen has reported sales for Aduhelm, but the financial performance has been significantly impacted by the aforementioned challenges, particularly the CMS coverage decision.

• 2022 Sales: Aduhelm generated approximately \$11 million in sales in the fourth quarter of 2022 and around \$4 million in the first quarter of 2023, indicating a significant decline from initial projections [12, 13].
• Strategic Shift: In January 2024, Biogen announced it would discontinue the development and commercialization of Aduhelm, transferring rights to a joint venture and ceasing U.S. sales by the end of June 2024 [14]. This decision reflects the drug's limited commercial viability and the company's strategic focus on other pipeline assets, including its co-developed drug with Eisai, lecanemab (Leqembi) [14].

The financial outlook for QUIDEX (Aduhelm) as a standalone product is therefore negative, with the drug slated for discontinuation.

Key Takeaways

QUIDEX (aducanumab), marketed as Aduhelm, has faced significant headwinds due to its controversial regulatory approval, questionable clinical efficacy, and restrictive reimbursement policies. While it demonstrated the ability to reduce amyloid-beta plaques, the clinical benefit was debated and not consistently shown across pivotal trials.

• Regulatory Uncertainty: Accelerated approval was based on a surrogate endpoint, with confirmatory trials pending and a complex regulatory history.
• Limited Market Access: The CMS National Coverage Determination significantly curtailed Medicare coverage, impacting U.S. sales.
• Intense Competition: The Alzheimer's disease market is becoming increasingly crowded with promising disease-modifying therapies.
• Discontinuation: Biogen has announced the discontinuation of Aduhelm's development and commercialization, effective mid-2024, due to its limited commercial viability. The company is focusing on its successful Alzheimer's drug, Leqembi.

FAQs

1. Will QUIDEX (Aduhelm) continue to be available after mid-2024? No. Biogen has announced that it will cease U.S. sales of Aduhelm by the end of June 2024 and is discontinuing its development and commercialization [14].

2. What was the main reason for the FDA's initial accelerated approval of Aduhelm? The FDA granted accelerated approval based on Aduhelm's ability to reduce amyloid-beta plaques in the brain, a surrogate endpoint that is reasonably likely to predict clinical benefit, despite debate regarding the drug's impact on cognitive decline [3, 4].

3. What are the primary safety concerns associated with Aduhelm? The main safety concerns are amyloid-related imaging abnormalities (ARIA), which include ARIA-E (edema) and ARIA-H (microhemorrhages), requiring careful monitoring with MRI scans [3].

4. How does Aduhelm's performance compare to other approved Alzheimer's drugs? Aduhelm's commercial performance has been significantly weaker than anticipated due to regulatory and reimbursement challenges. In contrast, Biogen's co-developed drug, lecanemab (Leqembi), has achieved traditional FDA approval and demonstrated stronger clinical efficacy signals and market uptake [10, 14].

5. What is Biogen's current strategy in the Alzheimer's disease market? Following the discontinuation of Aduhelm, Biogen is prioritizing its partnership with Eisai on lecanemab (Leqembi), which has secured traditional FDA approval and represents the company's core asset in the Alzheimer's disease therapeutic area [14].

Citations

[1] Cummings, J., et al. (2021). Aducanumab: Appropriate Use Recommendations. The Journal of Prevention of Alzheimer's Disease, 8(4), 398-410. [2] Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297(5580), 353-356. [3] U.S. Food and Drug Administration. (2021, June 7). FDA Grants Accelerated Approval to Aducanumab for Alzheimer's Disease. FDA News Release. [4] U.S. Food and Drug Administration. (2021). Aduhelm FDA Approval Letter. [5] FDA Advisory Committee Meeting, November 2020. (Meeting materials and transcript available on FDA website). [6] U.S. Food and Drug Administration. (2022, April 27). FDA Revises Labeling for Alzheimer's Drug Aduhelm. FDA News Release. [7] European Medicines Agency. (2021, December 17). European Medicines Agency recommends against the granting of a marketing authorisation for Aduhelm. EMA Press Release. [8] Hoffmann, S., et al. (2021). Aducanumab for Alzheimer’s Disease: The Clinical Data. The Journal of Prevention of Alzheimer's Disease, 8(4), 376-381. [9] Centers for Medicare & Medicaid Services. (2022, April 7). National Coverage Determination for Alzheimer's Disease Anti-Amyloid Monoclonal Antibody Treatment. NCD Manual Section. [10] Eisai Inc. & Biogen Inc. (2023, July 6). FDA Grants Traditional Approval to Leqembi (lecanemab-irgb) for Patients with Early Alzheimer’s Disease. Joint Press Release. [11] Eli Lilly and Company. (2023). Donanemab Phase 3 Clinical Trial Data. Investor Presentations and SEC Filings. [12] Biogen Inc. (2023, January 26). Biogen Reports Fourth Quarter and Full Year 2022 Results. Press Release. [13] Biogen Inc. (2023, April 20). Biogen Reports First Quarter 2023 Results. Press Release. [14] Biogen Inc. (2024, January 24). Biogen Announces Strategic Portfolio Prioritization and Pipeline Advancement. Press Release.